AKAO 2017 Annual Report

Achaogen, Inc. Consolidated Statements of Contingently Redeemable Common Stock and Stockholders’ Equity (in thousands except for share amounts) Contingently Redeemable Common Stock Common Stock Additional Paid-In Capital Accumulated Deficit Accumulated Other Comprehensive Loss Total Stockholders’ Equity Shares Amount Shares Amount Balance at December 31, 2014 .......................................................... — $ — 17,907,135 18 213,527 (148,900) (32) 64,613 Issuance of common stock under "at-the-market"equity offering sales agreement, less issuance costs.............................. — — 197,838 — 1,319 — — 1,319 Issuance of common stock under stock plans ............................. — — 228,504 — 1,053 — — 1,053 Issuance of common stock under ESPP...................................... — — 61,742 — 300 — — 300 Stock-based compensation expense ............................................ — — — — 2,983 — — 2,983 Unrealized loss on available-for-sale securities, net of taxes......... — — — — — — (16) (16) Net loss........................................................................................ — — — — — (27,093) — (27,093) Balance at December 31, 2015 .......................................................... — — 18,395,219 18 219,182 (175,993) (48) 43,159 Issuance of common stock under "at-the-market" equity offering sales agreement, less issuance costs.............................. — — 907,711 1 3,826 — — 3,827 Issuance of common stock under stock plans ............................. — — 103,912 — 65 — — 65 Issuance of common stock under ESPP...................................... — — 145,724 — 401 — — 401 Issuance of common stock upon an underwritten public offering, net of issuance costs..................................................... — — 7,475,000 7 94,540 — — 94,547 Issuance of common stock upon sale of common stock under the private placement, net of issuance costs ............................... — — 7,999,996 8 22,579 — — 22,587 Issuance of common stock upon exercise of warrants................ — — 610,490 1 9,487 — — 9,488 Stock-based compensation expense ............................................ — — — — 3,847 — — 3,847 Unrealized gain on available-for-sale securities, net of taxes ........ — — — — — — 41 41 Net loss........................................................................................ — — — — — (71,227) — (71,227) Balance at December 31, 2016 .......................................................... — — 35,638,052 35 353,927 (247,220) (7) 106,735 Issuance of contingently redeemable common stock under private placement ........................................................................ 407,331 10,000 — — — — — — Issuance of common stock under stock plans ............................. — — 413,333 1 1,644 — — 1,645 Issuance of common stock under ESPP...................................... — — 186,455 — 1,323 — — 1,323 Issuance of common stock upon an underwritten public offering, net of issuance costs..................................................... — — 5,750,000 6 121,186 — — 121,192 Issuance of common stock upon exercise of warrants................ — — 119,844 — 2,506 — — 2,506 Stock-based compensation expense ............................................ — — — — 14,172 — — 14,172 Unrealized gain on available-for-sale securities, net of taxes ........ — — — — — — 7 7 Net loss........................................................................................ — — — — — (125,618) (125,618) Balance at December 31, 2017 .......................................................... 407,331 10,000 42,107,684 42 494,758 (372,838) — 121,962 See accompanying notes to consolidated financial statements. 107